Repligen Corporation (RGEN) News
Follow Repligen Corporation (RGEN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
Shares of pharmaceutical companies Kodiak Sciences Inc. (KOD), Repligen Corp. (RGEN) and Biogen Inc. (BIIB) surged to fresh 52-week highs on Monday amid positive trial results and strong earnings reports.KOD stock surged
EARNINGS | Sep 29, 2026, 04:24 AM UTC
L
RGEN: Robust growth, strategic acquisitions, and tech innovation drive a positive outlook for margins and revenue
Strong organic growth and upgraded guidance were driven by standout performance in protein and analytics, while strategic acquisitions like BioLife Solutions are set to diversify and accelerate growth. Technology adoptio
EARNINGS | Sep 09, 2026, 06:23 PM UTC
L
UBS raises Repligen price target to $225 from $195
UBS raised its Repligen price target to $225.00 per share from $195.00.
EQUITY | Sep 09, 2026, 06:06 PM UTC
L
Repligen to Present at Wells Fargo Healthcare Conference
Repligen Corporation plans to present at the Wells Fargo 21st Annual Healthcare Conference, according to TradingView News.
EQUITY | Aug 26, 2026, 11:37 AM UTC
L
RGEN - Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference
RGEN - Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference
EQUITY | Aug 26, 2026, 11:30 AM UTC
L
RGEN hits 52-week highs, up 5%
RGEN is at 52-week highs, with the move indicated as +5% in the supplied market alert.
EQUITY | Aug 20, 2026, 03:24 PM UTC
L
Largest premium to VWAP COTY (+3.75%) TEM (+3.69%) ILMN (+3.3%) WHR (+2.89%) NDSN (+2.71%) RGEN (+2.55%) TPL (+2.49%) DG (+2.37%) LITE (+2.3
Largest premium to VWAP COTY (+3.75%) TEM (+3.69%) ILMN (+3.3%) WHR (+2.89%) NDSN (+2.71%) RGEN (+2.55%) TPL (+2.49%) DG (+2.37%) LITE (+2.36%) DE (+2.32%) (Russell 1000 names)
EQUITY | Aug 20, 2026, 03:22 PM UTC
M
Merck and Moderna report interim Phase 3 vaccine data hits endpoint
Merck and Moderna said interim Phase 3 data for Moderna’s personalized cancer vaccine met its primary endpoint, with Wells noting potential beneficiaries include RGEN, DHR, TMO and MRVI.
EQUITY | Aug 20, 2026, 01:25 PM UTC
H
RGEN Raised to $185 PT
RGEN price target raised to $185
EQUITY | Jul 29, 2026, 01:22 PM UTC
L
RGEN Raise ests and PT to $200 as Repligen continues to perform above heightened expectations and seemingly against a whack-a-mole of invest
RGEN Raise ests and PT to $200 as Repligen continues to perform above heightened expectations and seemingly against a whack-a-mole of investor fears @ DBAB
EQUITY | Jul 29, 2026, 12:44 PM UTC
H
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Tuesday. Shares of Sherwin-Williams Co (NYSE: SHW ) rose sharply after the company reported better-than-expected second-quarter financial resu
EARNINGS | Jul 28, 2026, 02:05 PM UTC
L
Repligen raises FY26 EPS view to $2.03-$2.09 from $1.97-$2.05, consensus $2.00
Raises FY26 revenue view...
EARNINGS | Jul 28, 2026, 11:10 AM UTC
L
Repligen reports Q2 adjusted EPS 54c, consensus 45c
Reports Q2 revenue...
EARNINGS | Jul 28, 2026, 11:06 AM UTC
L
RGEN Repligen RESULTS: Q2, Q2 ADJ EPS $0.54 vs. EST $0.45, Q2 ADJ Operating Income $34M, Q2 REV $204M vs. EST $201.5M
RGEN Repligen RESULTS: Q2, Q2 ADJ EPS $0.54 vs. EST $0.45, Q2 ADJ Operating Income $34M, Q2 REV $204M vs. EST $201.5M
EARNINGS | Jul 28, 2026, 11:02 AM UTC
L
Repligen Raises FY2026 Adj EPS Guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 Est; Raises FY2026 Sales Guidance from $803.000M-$833.000M
Repligen (NASDAQ: RGEN ) raises FY2026 Adj EPS guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 analyst estimate. Raises FY2026 sales outlook from $803.000 million-$833.000 million to $813.000 million-$835.000 million v
EARNINGS | Jul 28, 2026, 11:01 AM UTC
L
Largest discount to VWAP QS (-6.31%) ACI (-5.23%) MEDP (-4.53%) MOH (-4.13%) RGEN (-3.89%) LITE (-3.46%) IQV (-3.41%) AUR (-3.37%) CMCSA (-3
Largest discount to VWAP QS (-6.31%) ACI (-5.23%) MEDP (-4.53%) MOH (-4.13%) RGEN (-3.89%) LITE (-3.46%) IQV (-3.41%) AUR (-3.37%) CMCSA (-3.3%) HUBS (-3.25%) (Russell 1000 names)
EQUITY | Jul 23, 2026, 03:42 PM UTC
L
Near 200dma resistance VZ RGEN DRI FDS BJ LW THC
Near 200dma resistance VZ RGEN DRI FDS BJ LW THC
EQUITY | Jul 22, 2026, 04:09 PM UTC
L
RGEN Repligen Corp: if deal terminated under some circumstances, Biolife may be required to pay Repligen a termination fee of $59M
RGEN Repligen Corp: if deal terminated under some circumstances, Biolife may be required to pay Repligen a termination fee of $59M
EQUITY | Jul 22, 2026, 01:00 PM UTC
L
RGEN said it would buy Biolife Solutions (BLFS) in a cash-and-stock deal valued at about $1.5B, to expand its presence in the fast-growing c
RGEN said it would buy Biolife Solutions (BLFS) in a cash-and-stock deal valued at about $1.5B, to expand its presence in the fast-growing cell therapy market; Biolife shareholders will receive $11.25 in cash and 0.1442
EQUITY | Jul 22, 2026, 10:19 AM UTC
H
TMO DHR RGEN SOAGY Bioprocessing Names Likely to Deliver Most 'Leverage' in Tools This Earnings Season @ KEYB
TMO DHR RGEN SOAGY Bioprocessing Names Likely to Deliver Most 'Leverage' in Tools This Earnings Season @ KEYB
EARNINGS | Jul 15, 2026, 11:14 AM UTC
L
RGEN - Regeneron's dupilumab granted orphan drug designation per FDA website
RGEN - Regeneron's dupilumab granted orphan drug designation per FDA website
REGULATION | Jul 14, 2026, 09:08 PM UTC
H
Repligen upgraded to Buy from Hold at Benchmark
Benchmark analyst Robert Wasserman upgraded Repligen to Buy from Hold with an $185 price target, citing improved quarterly financial performance as well as increased valuations for comparable bioprocessing stocks. Replig
EQUITY | Jul 07, 2026, 10:30 AM UTC